CLinical impact through AI-assisted MS care

Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system.

Since there is no cure available yet for MS, the primary therapeutic goal for MS patients is to slow down disability progression and to reduce relapses at early stages of the disease.

Despite 19 available disease modifying treatments (DMTs), the large heterogeneity of the disease, further complicated by the high prevalance of comorbidities and multipharmacy, and the limited understanding of the working mechanisms DMT thereon results in a poor and variable treatment response in a real-world setting.

The CLAIMS project is a public-private partnership aiming to address this and make precision medicine for MS patients a reality through data-driven prognosis and treatment advice, in order to better slow down disease progression and eventually conversion to progressive MS.

We will develop, validate and submit for regulatory approval a companion diagnostic platform, which offers the MS care team a holistic view of the patient through the visualization of the clinical and subclinical biomarkers and the prediction of the expected disease trajectory under different treatments.

For biomarker extraction and treatment prediction, state-of-the-art technologies that allow a reliable and scalable implementation across the world will be used.

We believe this platform will initiate the paradigm shift from a trial-and-error, experienced-based treatment of MS patients to a first-time-right, value-based holistic treatment management, and will, hence, improve patient outcomes at a lower total cost of care, enhance patient experience and improve the well-being of the care team.